Drug Response Dx

Drug Response Dx, headquartered in Hennigsdorf, Germany, was founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis. Their tests utilize a protein that predicts the individual effectiveness of TNF-alpha inhibitors, allowing for personalized treatment planning prior to medication administration. This approach facilitates timely initiation of treatment and increases the likelihood of positive patient outcomes. The company's biomarker set is prevalidated, and they have established proof of concept using serum samples from rheumatoid arthritis patients.